Physician profile
Eric Hagood
NPI 1205375318
$3,937.68
in general payments reported to CMS, 2019-2025
27 companies · $947 in 2025
The $947 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $777 · 2022: $716 · 2023: $700 · 2024: $798 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,211.87 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $726.62 | 2021-2025 | Relistor, Xifaxan, Trulance |
| Gilead Sciences, INC. | $334.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $275.68 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $248.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $194.17 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Indivior INC. | $172.40 | 2024-2025 | Sublocade |
| Pfizer INC. | $120.53 | 2021-2025 | |
| Exact Sciences Corporation | $103.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $61.05 | 2025 | |
| Antares Pharma, INC. | $52.86 | 2024-2025 | Xyosted, Tlando |
| Braeburn INC. | $52.30 | 2025 | Brixadi |
| Lilly USA, LLC | $51.07 | 2021-2023 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $46.91 | 2022-2023 | Quviviq |
| Eisai INC. | $41.38 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $41.25 | 2022-2025 | Rexulti |
| Dexcom, INC. | $31.93 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $28.07 | 2021-2022 | |
| Redhill Biopharma INC. | $21.15 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $19.15 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.61 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $14.96 | 2021 | |
| Merck Sharp & Dohme LLC | $14.69 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.46 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.38 | 2024 | Voquezna |
| Amarin Pharma, INC. | $14.21 | 2021 | |
| Orexo US, INC. | $13.10 | 2024 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hagood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.